 Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by Multiple Clinical Sites in Japan VANCOUVER, BC ACCESSWIRE May 19, 2021 RepliCel Life Sciences Inc. OTC PINK:REPCFTSXV:RPFRA:P6P2 RepliCel or the Company, a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained leading clinical research organization, Accerise Inc, with offices in Tokyo and Osaka, to lead the planning and preparations for clinical research studies of RepliCels skin rejuvenation RCS-01 and tendon regeneration RCT-01 cell therapy products in Japan. Accerise will support RepliCels clinical advisors, Professor Morita and Professor Kumai, in the design of the clinical study protocols, procuring the collaboration of all clinical sites, obtaining all necessary approvals from institutional research boards IRBs, oversight committees, and the Ministry of Health, Labour and Welfare MHLW including certification, training, and the establishment of the necessary systems for independent clinical study management to ensure the studies produce high-quality GCP-compliant data. 